Traitement des plaies

Leading the way in innovation and evidence to be showcased at EWMA 2014

Par : Mölnlycke Health Care, avril 18 2014Publié dans : Traitement des plaies

Mölnlycke Health Care has always been creating a legacy of leading the way in wound care management, and our planned activities at the EWMA 2014 congress are aimed at continuing this tradition. This years' booth will reflect the proud history of the Mölnlycke Health Care range of innovative wound care products which help minimise pain for the patient and trauma to the wound. It will also highlight the significant milestones in the publication of key clinical evidence.

Ever since the introduction of Mepitel® in 1990 to the launch of Mepilex® Transfer Ag in 2013, Mölnlycke Health Care has been leading the way in successfully developing products that professionals ask for and patients need – products that are supported by clinical evidence.

Visitors to Mölnlycke Health Care at EWMA 2014 will get a better understanding of how dressings with the unique and patented Safetac® technology can free patients from unnecessary suffering1 during their wound healing journey as well as an understanding of how using Mepilex® Border, as an adjunct to current prevention protocols can reduce pressure ulcer incidences2. Further, they will learn how Mepitel® Film can prevent radiotherapy-induced skin reactions3 and how Mepilex® Ag can reduce the cost of burns treatment4. We at Mölnlycke Health Care are proud of the level of clinical evidence that exist in support of our products.

Once a day during EWMA 2104 there will be an in-booth demonstration of Mölnlycke Health Care’s new WoundEL® electro stimulation system that supports wound care managers treating hard-to-heal chronic wounds while significantly reducing wound related pain5.

As a corporate congress sponsor Mölnlycke Health Care will host a symposium on Influencing Cost Effective Wound Care. This seminar aims to evaluate the current situation for purchasing decisions in wound care across Europe and beyond, in both the prevention and treatment of chronic wounds.

Mölnlycke Health Care is looking forward to meeting you at the EWMA 2014 congress in Madrid May 14-16.

 

References:
1) White, R. A multinational survey of the assessment of pain when removing dressings.  Wounds UK, 2008;4(1):14-22.
2) Santamaria., N et al A randomised controlled trial of the effectiveness of soft silicone multi-layered foam dressings in the prevention of sacral and heel pressure ulcers in trauma and critically ill patients: the border trial . Int Wound J 2013; doi: 10.1111/iwj.12101.
3) Herst, P.M., et al. Prophylactic use of Mepitel Film prevents radiation-induced
moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiother Oncol 2014, Jan 29 {Epub ahead of print}
4) Silverstein, P., et al. An open parallel, randomized, comparative, multicenter study to evaluate the cost-effectiveness, performance, tolerance, and safety of a silver-containing soft silicone foam. J Burn Care Res 2011;32(6):627-626.
5) Leloup, P., et al. The analgesic effect of electrostimulation (WoundEL) in the treatment of leg ulcers. International Wound Journal 2014;doi:10/1111/iwj.12211

Plus d’informations